How does ASAP's PB Ratio compare to its peers?

ASAP is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (1.5x).

How does ASAP's PB Ratio compare vs other companies in the SE Pharmaceuticals Industry?

ASAP is good value based on its Price-To-Book Ratio (0.4x) compared to the Swedish Pharmaceuticals industry average (4.9x).

What is ASAP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ASAP's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ASAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ASAP's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Asarina Pharma (OM:ASAP) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ASAP Stock Overview

A biotech company, researches and develops pharmaceutical products. More details

ASAP fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings have grown 30% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (SEK634K)

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue (SEK0)

Asarina Pharma AB (publ) Competitors

Pharmiva

OM:PHARM

SEK 9.7m

DanCann Pharma

NGM:DANCAN

DKK 17.9m

Stayble Therapeutics

OM:STABL

SEK 23.0m

Eevia Health Oyj

NGM:EEVIA

SEK 14.4m

Price History & Performance

Summary of all time highs, changes and price drops for Asarina Pharma
Historical stock prices
Current Share Price	SEK 0.028
52 Week High	SEK 1.32
52 Week Low	SEK 0.028
Beta	0.17
11 Month Change	-70.83%
3 Month Change	-95.56%
1 Year Change	-96.77%
33 Year Change	-98.86%
5 Year Change	-99.88%
Change since IPO	-99.92%

Recent updates

Companies Like Asarina Pharma (STO:ASAP) Could Be Quite Risky

Jun 09

Shareholder Returns

	ASAP	SE Pharmaceuticals	SE Market
7D	-39.9%	0.9%	-0.2%
1Y	-96.8%	9.3%	11.8%

Return vs Industry: ASAP underperformed the Swedish Pharmaceuticals industry which returned 68.2% over the past year.

Return vs Market: ASAP underperformed the Swedish Market which returned 25.1% over the past year.

Price Volatility

Is ASAP's price volatile compared to industry and market?
ASAP volatility
ASAP Average Weekly Movement	28.5%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: ASAP's share price has been volatile over the past 3 months.

Volatility Over Time: ASAP's weekly volatility has increased from 18% to 29% over the past year.

About the Company

Founded	Employees	CEO	Website
2005	6	Peter Nordkild	www.asarinapharma.com

Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its’s product is Sepranolone, which is used for the treatment of allopregnanolone-induced stress- and compulsivity-driven disorders from Tourette syndrome to Obsessivecompulsive disorder syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016.

Asarina Pharma AB (publ) Fundamentals Summary

How do Asarina Pharma's earnings and revenue compare to its market cap?
ASAP fundamental statistics
Market cap	SEK 633.96k
Earnings (TTM)	-SEK 12.83m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ASAP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASAP income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 12.83m
Earnings	-SEK 12.83m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.57
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	60.6%

How did ASAP perform over the long term?

See historical performance and comparison

This company listing is no longer active

ASAP Stock Overview

Rewards

Risk Analysis

Asarina Pharma AB (publ) Competitors

OM:PHARM

SEK 9.7m

NGM:DANCAN

DKK 17.9m

OM:STABL

SEK 23.0m

NGM:EEVIA

SEK 14.4m

Price History & Performance

Recent News & Updates

Nasdaq Stockholm AB Decides to Delist the Shares in Asarina Pharma from Nasdaq First North Growth Market

Asarina Pharma Applies for Delisting of Shares from Nasdaq First North Growth Market

Asarina Pharma Applies for Delisting of Shares from Nasdaq First North Growth Market

New major risk - Share price stability

Asarina Pharma AB (publ), Annual General Meeting, Jun 15, 2024

Asarina Pharma AB (publ) to Report Fiscal Year 2023 Final Results on May 23, 2024

Recent updates

Nasdaq Stockholm AB Decides to Delist the Shares in Asarina Pharma from Nasdaq First North Growth Market

Asarina Pharma Applies for Delisting of Shares from Nasdaq First North Growth Market

Asarina Pharma Applies for Delisting of Shares from Nasdaq First North Growth Market

New major risk - Share price stability

Asarina Pharma AB (publ), Annual General Meeting, Jun 15, 2024

Asarina Pharma AB (publ) to Report Fiscal Year 2023 Final Results on May 23, 2024

Asarina Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 17, 2024

Asarina Pharma AB (publ) to Report First Half, 2023 Results on Aug 23, 2023

Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America

Insufficient new directors

Asarina Pharma AB (publ) to Report Fiscal Year 2022 Results on Apr 18, 2023

Asarina Pharma Completes Recruitment of Patients to its Phase IIa Clinical Study in Tourette Syndrome

Asarina Pharma AB (publ) to Report Second Half, 2022 Results on Feb 25, 2023

Asarina Pharma AB (publ) to Report Q1, 2022 Results on May 25, 2022

Asarina Pharma AB (Publ) Announces That `First Patient First Visit' Has Taken Place in Its Phase Ii A Clinical Study in Tourette Syndrome At Bispebjerg University Hospital, Copenhagen

Asarina Pharma Receives Final Approval for Phase IIa Tourette Study

Pmdd Phase Iib Study, Including Post-Hoc Analysis Showing ‘Significant Treatment Effect

Asarina Pharma Reports Topline Results in Phase IIa Menstrual Migraine Study

Companies Like Asarina Pharma (STO:ASAP) Could Be Quite Risky

The US Patent and Trademark Office Grants Asarina Pharma's Patent for Sepranolone for the Treatment of Tourette, Obsessive-Compulsive Disorder and Pathological Gambling

Asarina Pharma AB (publ) Receives Approval of CTA for Phase IIa Tourette Study

Asarina Pharma AB (publ) to Report Q1, 2021 Results on May 18, 2021

New 90-day low: kr5.64

New 90-day low: kr5.92

New 90-day low: kr6.04

New 90-day low: kr6.12

Asarina Pharma AB (publ) to Report Fiscal Year 2020 Final Results on May 12, 2021

New 90-day low: kr6.28

Asarina Pharma AB (Publ) Reaches Full Patient Enrolment in Its Phase Iia Menstrual Migraine (Mm) Study

Shareholder Returns

Price Volatility

About the Company

Asarina Pharma AB (publ) Fundamentals Summary

0.0x

0.0x

Earnings & Revenue